Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.
Lexaria Bioscience Catalysts and Price Analysis
A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.
Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.
Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.
Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the critical technical level should pave the way for bulls to push the stock to the $0.70 mark, the next substantial resistance level.
For the stock to turn bullish after the underperformance of the past year, it needs to rise and find support above the $1 a share level. Conversely, failure to take out the critical resistance level would leave the stock susceptible to continued short-selling pressure.
About Lexaria Bioscience
Lexaria Bioscience bills itself as a global innovator of drug delivery platforms. Its flagship product is DehydraTECH technology designed to enhance the way active pharmaceutical ingredients enter the bloodstream. The company also operates a licensed in-house research laboratory that holds a robust intellectual property portfolio with 16 patents.
DehydraTECH Technology Strong demand
After a roller coaster 2019, the tide is slowly moving in favor of Lexaria Bioscience as investors take note of the milestone achieved that affirm long-term prospects. For instance, the company opened discussions with a number of Fortune 500 style companies that continue to ask about its DehydraTECH technology for use in the delivery of cannabis ingredients.
In addition to positioning DehydraTECH for use in the burgeoning cannabis industry, the company is also looking to gain approval for its use in the next-generation nicotine products within America and around the world. The technology has already attracted interest from Altria, a heavyweight in combustible and non-combustible tobacco products.
“Lexaria strongly believes that, given the choice, many of the world’s one billion smokers would elect to experience their nicotine in a manner that does not rely on either smoking or vaping, and Lexaria can help enable these alternatives,” said Chris Bunka, CEO of Lexaria Bioscience and Lexaria Nicotine.
Likewise, the company is looking to build upon a contractual relationship it inked with a GMP certified FDA registered production company. Under the terms of the agreement, the company is looking to get enhanced DehydraTECH powders for marketing in the U.S. The deal should help the company meet the strong demand from many companies looking for DehydraTECH bulk powders for use in specific product lines.
IP Strategy and Revenue Growth Outlook
The company’s IP strategy is already bearing fruits following the securing of patents for the use of DehydraTECH for treatment of various health conditions such as heart disease and Alzheimer in Australia
Lexaria Bioscience has also started to experience an increase in revenue, expected to support sustainable and supportive growth. Given the growing clientele base, management expects revenues to more than double in 2020.
Lexaria Bioscience shares appear to be undervalued, given the milestones achieved that positions the company for accelerated growth in 2020. With the company projecting double-digit revenue growth at the back of the growing demand of the flagship DehydraTECH technology, the future certainly looks bright.
That said, the stock looks set to continue climbing higher after a steep pullback in 2019, on renewed investor interest, amidst improving fundamentals.
We will be updating our subscribers as soon as we know more. For the latest updates on Lexaria Bioscience, sign up below!
Disclosure: We have no position in Lexaria Bioscience and have not been compensated for this article.
Forget APHA and ACB, Buy GTBIF and TCNNF
There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).
On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.
There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.
Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.
The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…